Clear laws giving intellectual property rights to human inventors who use artificial intelligence will allow us to take advantage of the remarkable advances AI can bring to biotechnology, a biotech patent expert told Congress on April 10.
“Our patent law should support, not hinder, the responsible use of AI to achieve transformative results for the economy and human health,” said Claire Laporte, Ginkgo Fellow and former Head of Intellectual Property at Ginkgo Bioworks. “The last thing we should do is discourage scientists from using the best tools available to them.”
Laporte, whose company is a member of the Biotechnology Innovation Organization (BIO) Board of Directors, testified at a hearing hosted by the House Judiciary Subcommittee on Courts, Intellectual Property, and the Internet, “IP Protection for AI-Assisted Inventions and Creative Works.”
Bio.News: bio.news/feder...
April 10, 2024
10 апр 2024
